Robert C. Smallridge, M.D.

Closed for Enrollment

• A Phase IIA, Open-Label Study to Assess the Safety and Efficacy of a Single or Multiple Intravenous (IV) Dose of VB-111 in Subjects with Advanced Differentiated Thyroid Cancer (DTC) Rochester, Minn., Jacksonville, Fla.

  The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.